남성유방암 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "남성유방암" in Korean language version.

refsWebsite

Global rank Korean rank

4^th place

2^nd place

3^rd place

11^th place

310^th place

doi.org

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (November 2018). “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries”. 《CA: A Cancer Journal for Clinicians》 68 (6): 394–424. doi:10.3322/caac.21492. PMID 30207593. S2CID 52188256.
Zattarin E, Ligorio F, Nichetti F, Bianchi G, Capri G, de Braud F (December 2021). “Prolonged benefit from palbociclib plus letrozole in heavily pretreated advanced male breast cancer: case report”. 《Tumori》 107 (6): NP15–NP19. doi:10.1177/0300891620976981. PMID 33297845. S2CID 228089361.
Zheng G, Leone JP (2022). “Male Breast Cancer: An Updated Review of Epidemiology, Clinicopathology, and Treatment”. 《Journal of Oncology》 2022: 1734049. doi:10.1155/2022/1734049. PMC 9155932. PMID 35656339.
Khan NA, Tirona M (March 2021). “An updated review of epidemiology, risk factors, and management of male breast cancer”. 《Medical Oncology (Northwood, London, England)》 38 (4): 39. doi:10.1007/s12032-021-01486-x. PMID 33721121. S2CID 232237548.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (November 2018). “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries”. 《CA: A Cancer Journal for Clinicians》 68 (6): 394–424. doi:10.3322/caac.21492. PMID 30207593. S2CID 52188256.
Zattarin E, Ligorio F, Nichetti F, Bianchi G, Capri G, de Braud F (December 2021). “Prolonged benefit from palbociclib plus letrozole in heavily pretreated advanced male breast cancer: case report”. 《Tumori》 107 (6): NP15–NP19. doi:10.1177/0300891620976981. PMID 33297845. S2CID 228089361.
Benassai G, Miletti A, Calemma F, Furino E, De Palma GD, Quarto G (2020). “Male breast cancer: an update”. 《Annali Italiani di Chirurgia》 91: 359–365. PMID 33055389.
Zheng G, Leone JP (2022). “Male Breast Cancer: An Updated Review of Epidemiology, Clinicopathology, and Treatment”. 《Journal of Oncology》 2022: 1734049. doi:10.1155/2022/1734049. PMC 9155932. PMID 35656339.
Khan NA, Tirona M (March 2021). “An updated review of epidemiology, risk factors, and management of male breast cancer”. 《Medical Oncology (Northwood, London, England)》 38 (4): 39. doi:10.1007/s12032-021-01486-x. PMID 33721121. S2CID 232237548.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (November 2018). “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries”. 《CA: A Cancer Journal for Clinicians》 68 (6): 394–424. doi:10.3322/caac.21492. PMID 30207593. S2CID 52188256.
Zattarin E, Ligorio F, Nichetti F, Bianchi G, Capri G, de Braud F (December 2021). “Prolonged benefit from palbociclib plus letrozole in heavily pretreated advanced male breast cancer: case report”. 《Tumori》 107 (6): NP15–NP19. doi:10.1177/0300891620976981. PMID 33297845. S2CID 228089361.
Khan NA, Tirona M (March 2021). “An updated review of epidemiology, risk factors, and management of male breast cancer”. 《Medical Oncology (Northwood, London, England)》 38 (4): 39. doi:10.1007/s12032-021-01486-x. PMID 33721121. S2CID 232237548.